A number of clinical studies established that different strategies of immunization, including recombinant viruses, DNA or antiidiotypic antibodies can generate a CEA-specific cytotoxic T lymphocyte (CTL) response with anti-tumor activity in cancer patients and in mice [13-15]. Here, CEACAM5 is linked to neoplasm.